Email
Print
Next Generation Cancer Diagnostics Market - Forecast(2024 - 2030)
1. Next Generation Cancer Diagnostics Market - Overview
1.1 Definitions and Scope
2. Next Generation Cancer Diagnostics Market - Executive summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by type of Application
2.3 Key Trends segmented by Geography
3. Next Generation Cancer Diagnostics Market
3.1 Comparative analysis
3.1.1 Product Benchmarking - Top 10 companies
3.1.2 Top 5 Financials Analysis
3.1.3 Market Value split by Top 10 companies
3.1.4 Patent Analysis - Top 10 companies
3.1.5 Pricing Analysis
4. Next Generation Cancer Diagnostics Market - Startup companies Scenario Premium
4.1 Top 10 startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Next Generation Cancer Diagnostics Market - Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top 10 companies
6. Next Generation Cancer Diagnostics Market Forces
6.1 Drivers
6.2 Constraints
6.3 Challenges
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Next Generation Cancer Diagnostics Market - Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Product life cycle
7.4 Suppliers and distributors Market Share
8. Next Generation Cancer Diagnostics Market - By Technology (Market Size -$Million / $Billion)
8.1 NGS-based cancer diagnostics
8.2 qPCR & Multiplexing
8.3 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
8.4 Protein microarrays-based cancer diagnostics
8.5 DNA microarrays-based cancer diagnostics
9. Next Generation Cancer Diagnostics Market - By Type (Market Size -$Million / $Billion)
9.1 Next Generation Cancer Diagnostics By Cancer Type
9.1.1 Lung Cancer
9.1.2 Breast Cancer
9.1.3 Colorectal Cancer
9.1.4 Cervical Cancer
9.1.5 Other Type Of Cancer
9.2 Next Generation Cancer Diagnostics By Function Type
9.2.1 Therapeutic Monitoring
9.2.2 Companion Diagnostics
9.2.3 Prognostic Diagnostics
9.2.4 Cancer Screening
9.2.5 Risk Analysis
10. Next Generation Cancer Diagnostics - By Application (Market Size -$Million / $Billion)
10.1 Segment type Size and Market Share Analysis
10.2 Application Revenue and Trends by type of Application
10.3 Application Segment Analysis by Type
10.3.1 Next Generation Cancer Diagnostics Revenue Share By Application
10.3.2 Biomarker Development
10.3.3 Ctc Analysis
10.3.4 Proteomic Analysis
10.3.5 Epigenetic Analysis
10.3.6 Genetic Analysis
11. Next Generation Cancer Diagnostics - By Geography (Market Size -$Million / $Billion)
11.1 Next Generation Cancer Diagnostics Market - North America Segment Research
11.2 North America Market Research (Million / $Billion)
11.2.1 Segment type Size and Market Size Analysis
11.2.2 Revenue and Trends
11.2.3 Application Revenue and Trends by type of Application
11.2.4 Company Revenue and Product Analysis
11.2.5 North America Product type and Application Market Size
11.2.5.1 U.S
11.2.5.2 Canada
11.2.5.3 Mexico
11.2.5.4 Rest of North America
11.3 Next Generation Cancer Diagnostics- South America Segment Research
11.4 South America Market Research (Market Size -$Million / $Billion)
11.4.1 Segment type Size and Market Size Analysis
11.4.2 Revenue and Trends
11.4.3 Application Revenue and Trends by type of Application
11.4.4 Company Revenue and Product Analysis
11.4.5 South America Product type and Application Market Size
11.4.5.1 Brazil
11.4.5.2 Venezuela
11.4.5.3 Argentina
11.4.5.4 Ecuador
11.4.5.5 Peru
11.4.5.6 Colombia
11.4.5.7 Costa Rica
11.4.5.8 Rest of South America
11.5 Next Generation Cancer Diagnostics- Europe Segment Research
11.6 Europe Market Research (Market Size -$Million / $Billion)
11.6.1 Segment type Size and Market Size Analysis
11.6.2 Revenue and Trends
11.6.3 Application Revenue and Trends by type of Application
11.6.4 Company Revenue and Product Analysis
11.6.5 Europe Segment Product type and Application Market Size
11.6.5.1 U.K
11.6.5.2 Germany
11.6.5.3 Italy
11.6.5.4 France
11.6.5.5 Netherlands
11.6.5.6 Belgium
11.6.5.7 Denmark
11.6.5.8 Spain
11.6.5.9 Rest of Europe
11.7 Next Generation Cancer Diagnostics - APAC Segment Research
11.8 APAC Market Research (Market Size -$Million / $Billion)
11.8.1 Segment type Size and Market Size Analysis
11.8.2 Revenue and Trends
11.8.3 Application Revenue and Trends by type of Application
11.8.4 Company Revenue and Product Analysis
11.8.5 APAC Segment - Product type and Application Market Size
11.8.5.1 China
11.8.5.2 Australia
11.8.5.3 Japan
11.8.5.4 South Korea
11.8.5.5 India
11.8.5.6 Taiwan
11.8.5.7 Malaysia
11.8.5.8 Hong kong
11.8.5.9 Rest of APAC
11.9 Next Generation Cancer Diagnostics - Middle East Segment and Africa Segment Research
11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
11.10.1 Segment type Size and Market Size Analysis
11.10.2 Revenue and Trend Analysis
11.10.3 Application Revenue and Trends by type of Application
11.10.4 Company Revenue and Product Analysis
11.10.5 Middle East Segment Product type and Application Market Size
11.10.5.1 Israel
11.10.5.2 Saudi Arabia
11.10.5.3 UAE
11.10.6 Africa Segment Analysis
11.10.6.1 South Africa
11.10.6.2 Rest of Middle East & Africa
12. Next Generation Cancer Diagnostics Market - Entropy
12.1 New product launches
12.2 M&A s, collaborations, JVs and partnerships
13. Next Generation Cancer Diagnostics Market - Industry / Segment Competition landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Top companies
13.1.2 Market Share by Region- Top 10 companies
13.1.3 Market Share by type of Application - Top 10 companies
13.1.4 Market Share by type of Product / Product category- Top 10 companies
13.1.5 Market Share at global level - Top 10 companies
13.1.6 Best Practises for companies
14. Next Generation Cancer Diagnostics Market - Key Company List by Country Premium
15. Next Generation Cancer Diagnostics Market Company Analysis
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Alkermes
15.3 Allergan / Geodon Ritcher
15.4 Astrazeneca
15.5 Bristol-Myers Squibb And Company/ Otsuka Pharmaceutical
15.6 Eli Lilly
15.7 Johnson Johnson
15.8 Pfizer
15.9 Sumitomo Dainippon Pharma
15.10 Summary
15.11 Vanda Pharmaceutical
15.12 Company 11
15.13 Company 12 & More
16.1 Abbreviations
16.2 Sources
17. Next Generation Cancer Diagnostics Market - Methodology
17.1 Research Methodology
17.1.1 Company Expert Interviews
17.1.2 Industry Databases
17.1.3 Associations
17.1.4 Company News
17.1.5 Company Annual Reports
17.1.6 Application Trends
17.1.7 New Products and Product database
17.1.8 Company Transcripts
17.1.9 R&D Trends
17.1.10 Key Opinion Leaders Interviews
17.1.11 Supply and Demand Trends
1.1 Definitions and Scope
2. Next Generation Cancer Diagnostics Market - Executive summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by type of Application
2.3 Key Trends segmented by Geography
3. Next Generation Cancer Diagnostics Market
3.1 Comparative analysis
3.1.1 Product Benchmarking - Top 10 companies
3.1.2 Top 5 Financials Analysis
3.1.3 Market Value split by Top 10 companies
3.1.4 Patent Analysis - Top 10 companies
3.1.5 Pricing Analysis
4. Next Generation Cancer Diagnostics Market - Startup companies Scenario Premium
4.1 Top 10 startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Next Generation Cancer Diagnostics Market - Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top 10 companies
6. Next Generation Cancer Diagnostics Market Forces
6.1 Drivers
6.2 Constraints
6.3 Challenges
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Next Generation Cancer Diagnostics Market - Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Product life cycle
7.4 Suppliers and distributors Market Share
8. Next Generation Cancer Diagnostics Market - By Technology (Market Size -$Million / $Billion)
8.1 NGS-based cancer diagnostics
8.2 qPCR & Multiplexing
8.3 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
8.4 Protein microarrays-based cancer diagnostics
8.5 DNA microarrays-based cancer diagnostics
9. Next Generation Cancer Diagnostics Market - By Type (Market Size -$Million / $Billion)
9.1 Next Generation Cancer Diagnostics By Cancer Type
9.1.1 Lung Cancer
9.1.2 Breast Cancer
9.1.3 Colorectal Cancer
9.1.4 Cervical Cancer
9.1.5 Other Type Of Cancer
9.2 Next Generation Cancer Diagnostics By Function Type
9.2.1 Therapeutic Monitoring
9.2.2 Companion Diagnostics
9.2.3 Prognostic Diagnostics
9.2.4 Cancer Screening
9.2.5 Risk Analysis
10. Next Generation Cancer Diagnostics - By Application (Market Size -$Million / $Billion)
10.1 Segment type Size and Market Share Analysis
10.2 Application Revenue and Trends by type of Application
10.3 Application Segment Analysis by Type
10.3.1 Next Generation Cancer Diagnostics Revenue Share By Application
10.3.2 Biomarker Development
10.3.3 Ctc Analysis
10.3.4 Proteomic Analysis
10.3.5 Epigenetic Analysis
10.3.6 Genetic Analysis
11. Next Generation Cancer Diagnostics - By Geography (Market Size -$Million / $Billion)
11.1 Next Generation Cancer Diagnostics Market - North America Segment Research
11.2 North America Market Research (Million / $Billion)
11.2.1 Segment type Size and Market Size Analysis
11.2.2 Revenue and Trends
11.2.3 Application Revenue and Trends by type of Application
11.2.4 Company Revenue and Product Analysis
11.2.5 North America Product type and Application Market Size
11.2.5.1 U.S
11.2.5.2 Canada
11.2.5.3 Mexico
11.2.5.4 Rest of North America
11.3 Next Generation Cancer Diagnostics- South America Segment Research
11.4 South America Market Research (Market Size -$Million / $Billion)
11.4.1 Segment type Size and Market Size Analysis
11.4.2 Revenue and Trends
11.4.3 Application Revenue and Trends by type of Application
11.4.4 Company Revenue and Product Analysis
11.4.5 South America Product type and Application Market Size
11.4.5.1 Brazil
11.4.5.2 Venezuela
11.4.5.3 Argentina
11.4.5.4 Ecuador
11.4.5.5 Peru
11.4.5.6 Colombia
11.4.5.7 Costa Rica
11.4.5.8 Rest of South America
11.5 Next Generation Cancer Diagnostics- Europe Segment Research
11.6 Europe Market Research (Market Size -$Million / $Billion)
11.6.1 Segment type Size and Market Size Analysis
11.6.2 Revenue and Trends
11.6.3 Application Revenue and Trends by type of Application
11.6.4 Company Revenue and Product Analysis
11.6.5 Europe Segment Product type and Application Market Size
11.6.5.1 U.K
11.6.5.2 Germany
11.6.5.3 Italy
11.6.5.4 France
11.6.5.5 Netherlands
11.6.5.6 Belgium
11.6.5.7 Denmark
11.6.5.8 Spain
11.6.5.9 Rest of Europe
11.7 Next Generation Cancer Diagnostics - APAC Segment Research
11.8 APAC Market Research (Market Size -$Million / $Billion)
11.8.1 Segment type Size and Market Size Analysis
11.8.2 Revenue and Trends
11.8.3 Application Revenue and Trends by type of Application
11.8.4 Company Revenue and Product Analysis
11.8.5 APAC Segment - Product type and Application Market Size
11.8.5.1 China
11.8.5.2 Australia
11.8.5.3 Japan
11.8.5.4 South Korea
11.8.5.5 India
11.8.5.6 Taiwan
11.8.5.7 Malaysia
11.8.5.8 Hong kong
11.8.5.9 Rest of APAC
11.9 Next Generation Cancer Diagnostics - Middle East Segment and Africa Segment Research
11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
11.10.1 Segment type Size and Market Size Analysis
11.10.2 Revenue and Trend Analysis
11.10.3 Application Revenue and Trends by type of Application
11.10.4 Company Revenue and Product Analysis
11.10.5 Middle East Segment Product type and Application Market Size
11.10.5.1 Israel
11.10.5.2 Saudi Arabia
11.10.5.3 UAE
11.10.6 Africa Segment Analysis
11.10.6.1 South Africa
11.10.6.2 Rest of Middle East & Africa
12. Next Generation Cancer Diagnostics Market - Entropy
12.1 New product launches
12.2 M&A s, collaborations, JVs and partnerships
13. Next Generation Cancer Diagnostics Market - Industry / Segment Competition landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Top companies
13.1.2 Market Share by Region- Top 10 companies
13.1.3 Market Share by type of Application - Top 10 companies
13.1.4 Market Share by type of Product / Product category- Top 10 companies
13.1.5 Market Share at global level - Top 10 companies
13.1.6 Best Practises for companies
14. Next Generation Cancer Diagnostics Market - Key Company List by Country Premium
15. Next Generation Cancer Diagnostics Market Company Analysis
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Alkermes
15.3 Allergan / Geodon Ritcher
15.4 Astrazeneca
15.5 Bristol-Myers Squibb And Company/ Otsuka Pharmaceutical
15.6 Eli Lilly
15.7 Johnson Johnson
15.8 Pfizer
15.9 Sumitomo Dainippon Pharma
15.10 Summary
15.11 Vanda Pharmaceutical
15.12 Company 11
15.13 Company 12 & More
*Financials would be provided on a best efforts basis for private companies
16. Next Generation Cancer Diagnostics Market - Appendix16.1 Abbreviations
16.2 Sources
17. Next Generation Cancer Diagnostics Market - Methodology
17.1 Research Methodology
17.1.1 Company Expert Interviews
17.1.2 Industry Databases
17.1.3 Associations
17.1.4 Company News
17.1.5 Company Annual Reports
17.1.6 Application Trends
17.1.7 New Products and Product database
17.1.8 Company Transcripts
17.1.9 R&D Trends
17.1.10 Key Opinion Leaders Interviews
17.1.11 Supply and Demand Trends